A recent regulatory update in Brazil has reshaped clinical responsibilities within oral health practice. The country’s health authority, Anvisa, has authorised dentists to prescribe Mounjaro (tirzepatide) for obese patients diagnosed with obstructive sleep apnoea — a serious respiratory condition often overlooked in routine assessments. The new allowance broadens the therapeutic landscape but simultaneously places greater emphasis on professional caution, technical preparation, and coordinated care.
Originally developed for the management of type 2 diabetes, tirzepatide has demonstrated benefits in patients with obesity, including reductions in cervical and abdominal fat. These changes may lessen the severity of sleep apnoea, a link that has prompted Brazil to reassess how different health professionals may contribute to treatment pathways.
A Shift in Dental Practice and Therapeutic Responsibilities
Although dentists in Brazil already have prescribing autonomy under national law, the extension of Mounjaro’s use requires practitioners to deepen their understanding of the medication’s metabolic effects and potential systemic repercussions. Evidence from international studies has shown that weight-loss agents such as tirzepatide can influence respiratory mechanics and inflammatory responses in individuals with obesity, providing scientific basis for its expanded indication.
Given that many cases of sleep apnoea are first suspected during dental consultations — often when patients report chronic snoring, bruxism or persistent fatigue — the new measure seeks to accelerate access to treatment. However, Anvisa stresses that prescriptions must occur within controlled clinical environments, as obese patients frequently take multiple medications that may interact with tirzepatide.
Collaboration Becomes Essential, Not Optional
The Federal Council of Dentistry in Brazil advises that prescribing decisions must involve collaboration with other healthcare professionals. Recommended partners in the care process include:
physicians overseeing metabolic and endocrine conditions;
specialists responsible for sleep monitoring and diagnostic testing;
clinicians trained to check for pharmacological interactions;
experts in obesity management and respiratory health.
This integrative model aims to reduce adverse reactions and ensure consistent evaluation of clinical outcomes, particularly for patients living with complex comorbidities. International research on multidisciplinary approaches to sleep apnoea supports this strategy, noting that coordinated care improves treatment adherence and long-term symptom control.
Balancing Therapeutic Benefits With Safety Considerations
While tirzepatide may substantially improve sleep apnoea associated with obesity, its use is not without risks. Known adverse effects — including gastrointestinal symptoms and dose-related tolerability issues — require close monitoring. Clinical trials have demonstrated that medical supervision is essential for adjusting dosage and managing side effects, reinforcing the need for prudent decision-making among all prescribers.
For dentists in Brazil, the new authorisation marks progress but also signals a growing obligation: to expand clinical training, follow evidence-based guidelines, and maintain strong interprofessional communication. The reform seeks to improve patient access to therapy, yet it also underscores that safeguarding health remains the foremost priority.